Clean beat-and-raise on top of a clearly improving sector backdrop — and the most upbeat IDXX call in this cycle. Revenue $1.141B (+14.3% reported / +11.6% organic) beat $1.131B Street by +0.9%; EPS $3.47 (+17.2% YoY, +15% on a comparable basis) beat $3.41 by +1.8%. The variance was operational: CAG Dx recurring revenue grew ~11% organic globally (~11% U.S., ~12% Intl), driven by a ~1,100 bps premium to U.S. clinical visits (-1% in Q1, ~100 bps better than initial guide). Premium instrument placements drove +28% organic CAG instrument growth, including 1,100 inVue Dx analyzers (FY26 placement target reiterated at 5,500). Gross margin hit a record 63.4% (+100 bps YoY); comparable operating margin +100 bps. EPS bridge: +$0.09 SBC benefit, -$0.05 equity-investment loss, +$0.14 FX, before underlying operational gains. Guidance: RAISE, all volume. FY26 revenue $4.675-$4.760B (mid $4.7175B, +$42M vs prior; ~$32M operational + ~$10M FX); EPS $14.45-$14.90 (+$0.13 op + $0.05 FX - $0.05 equity loss); CAG Dx recurring organic raised ~70 bps to 8.7-10.7% (mid 9.7%); U.S. visit assumption improved to -1.5% (from -2%); price held at ~4% — "all volume driven." Tone: most positive of the past four quarters. Mgmt explicitly upgraded the industry outlook ("modest improvement in our sector outlook") for the first time this cycle. CEO transition: Jay Mazelsky → Mike Erickson after May annual meeting; AI roadmap reveal deferred to August Investor Day. Watch items: (1) inVue Dx F&A unconstrained launch in 2H'26 — most important catalyst; (2) US visit stabilization + aging-pet 5+ yr cohort (3rd straight quarter of positive non-well visits); (3) Cancer Dx menu expansion (mast cell tumor add later '26, 3rd test by YE'26, intl launch in EU/AU); (4) instrument revenue headwind in 2H as IDXX laps the heavy 2025 inVue ramp; (5) Middle East supply-chain disruption (modest, in Water). Trajectory verdict: organic re-accel from Q1'25 trough (+4.4%) peaked at +12.8% in Q4'25; Q1'26 +11.6% is the first deceleration of the new up-cycle (-120 bps QoQ organic), masked at the headline level by FX (+90 bps tailwind). "Mid-cycle, just past peak rate-of-change" — beats will be smaller, EPS leverage still working (+17% on +12% organic), but the easy phase is behind us. Read: thesis intact; quality of guide is high (volume-driven, sector-validated); incremental upside from F&A scale, intl ref-lab share gains, and a less-bad U.S. visit environment. Bear narrows; Street EPS gap (-$0.135) is FX/equity-loss optics, not operational.

Key Metrics Trends

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
CAG Dx recurring revenue	$780M	$808M	$783M	$758M	$806M	$878M	$873M	$850M	$920M
CAG Dx recurring revenue YoY %	-	-	-	-	+3.4%	+8.6%	+11.5%	+12.2%	+14.1%
Vet software/services/imaging	$75M	$79M	$79M	$80M	$82M	$86M	$88M	$91M	$91M
Vet software/services/imaging YoY %	-	-	-	-	+8.8%	+9.2%	+11.1%	+13.4%	+11.9%
CAG segment revenue	$889M	$922M	$892M	$870M	$920M	$1.0B	$1.0B	$998M	$1.1B
CAG segment revenue YoY %	-	-	-	-	+3.4%	+10.9%	+13.5%	+14.7%	+14.6%
Water revenue	$43M	$47M	$50M	$45M	$45M	$51M	$54M	$50M	$50M
Water revenue YoY %	-	-	-	-	+5.1%	+9.2%	+8.2%	+11.7%	+11.0%
LPD revenue	$28M	$30M	$29M	$35M	$29M	$32M	$34M	$38M	$32M
LPD revenue YoY %	-	-	-	-	+1.4%	+5.0%	+16.9%	+8.4%	+13.6%
Other revenue	$4M	$4M	$4M	$4M	$5M	$4M	$4M	$4M	$4M
Other revenue YoY %	-	-	-	-	+34.3%	+2.4%	+2.3%	+0.0%	-14.9%
Total revenue	$964M	$1.0B	$976M	$954M	$998M	$1.1B	$1.1B	$1.1B	$1.1B
Total revenue YoY %	-	-	-	-	+3.6%	+10.6%	+13.3%	+14.3%	+14.3%
Organic revenue growth	7.2%	6.7%	6.0%	5.8%	4.4%	9.7%	12.2%	12.8%	11.6%
Organic revenue growth YoY chg (bps)	-	-	-	-	-280	+300	+620	+700	+720
Gross margin %	61.5%	61.7%	61.1%	59.8%	62.4%	62.6%	61.8%	60.3%	63.4%
Gross margin % YoY chg (bps)	-	-	-	-	+90	+90	+70	+50	+100
Operating margin %	31.0%	26.3%	31.2%	27.4%	31.7%	33.6%	32.1%	28.9%	31.8%
Operating margin % YoY chg (bps)	-	-	-	-	+70	+730	+90	+150	+10
Diluted EPS	$2.81	$2.44	$2.80	$2.62	$2.96	$3.63	$3.40	$3.08	$3.47
Diluted EPS YoY %	-	-	-	-	+5.3%	+48.8%	+21.4%	+17.6%	+17.2%
Adjusted EBITDA (TTM)	$1.3B	$1.3B	$1.3B	$1.3B	$1.4B	$1.5B	$1.5B	$1.6B	$1.6B
Adjusted EBITDA (TTM) YoY %	-	-	-	-	+3.5%	+14.1%	+14.7%	+17.8%	+20.4%

_Trajectory: mid-cycle, just past peak rate-of-change. Organic growth troughed at +4.4% in Q1'25 after a five-quarter decel, then ripped through a four-quarter re-acceleration to +9.7% → +12.2% → +12.8%, driven by inVue Dx adoption, premium hematology, and recovering U.S. visit trends. Q1'26 organic +11.6% marks the first decel of the new up-cycle (-120 bps QoQ); reported revenue held at +14.3% only because FX flipped to a ~90 bps tailwind. CAG Dx recurring organic stair-stepped from +4.5% to +11.0% over the last 5 quarters. Gross margin hit a record 63.4% (+100 bps YoY); EPS YoY +17.2% on +11.6% organic confirms operating leverage still working — but the second-derivative has flipped negative for the first time since the trough. "Good but not getting better" zone — incremental beats will be smaller, and upside requires inVue F&A unconstrained ramp + U.S. visit stabilization. Two-year stack still expanding (16.0 pts) but slower than Q4'25 (17.2 pts)._

Beat/Miss

Guidance

Catalysts

Street Q&A

Contradictions

Read-Throughs

This Quarter vs Consensus

Metric	Consensus	Actual	Variance	Read
Revenue	$1.131B (Zacks/StreetAccount)	$1.141B	+$10M / +0.9%	Beat — narrowest of L4Q streak; Street caught up
Reported Revenue YoY	—	+14.3%	—	Held at Q4'25 peak; FX +90 bps masking organic decel
Organic Revenue Growth	~9-10%	+11.6%	+~150-200 bps	Beat — but -120 bps QoQ from Q4'25 peak
CAG Dx Recurring Organic	~9.5%	+11.0%	+~150 bps	Beat — accelerating YoY (vs 4.5% PY)
Comparable Op Margin	~+50 bps expansion	+100 bps comparable	+~50 bps	Beat — gross-margin led
Gross Margin %	~62.5%	63.4%	+90 bps	Record — first time over 63%
EPS (diluted)	$3.41 (Zacks)	$3.47	+$0.06 / +1.8%	Beat — comparable EPS +15%
U.S. clinical visits	~-2% (initial guide)	-1.0% (mgmt disclosed)	+~100 bps	Beat — drives FY visit guide upgrade to -1.5%
inVue Dx placements	~1,200-1,300 (sell-side)	1,100	-100-200 units	Slight miss; FY 5,500 reaffirmed
L4Q rev beat rate	—	4/4 = 100%	—	Consistent Beater
L4Q EPS beat rate	—	4/4 = 100%	—	Consistent Beater
L8Q rev beat rate	—	6/8 = 75%	—	Consistent (1 in-line, 1 small miss)
L8Q EPS beat rate	—	7/8 = 88%	—	Q2'24 the only miss (litigation accrual)

Pattern: Consistent Beater, magnitude moderating as Street catches up. IDXX has now beat revenue 4/4 and EPS 4/4 in the L4Q, with EPS beat magnitudes of +3.5% / +9.7% / +8.6% / +5.1% / +1.8% (Q1'25→Q1'26) — the trajectory is improving-then-moderating as the Street has re-rated post-inVue/Cancer Dx innovation tailwind. Q1'26 EPS beat of +1.8% is the smallest in the streak. Revenue beats compressed similarly: +1.8% / +3.6% / +3.3% / +1.9% / +0.9%. Quality of the print is higher than the magnitude suggests: comparable operating margin +100 bps, gross margin a record 63.4%, organic CAG Dx recurring re-accelerated to +11.0% (vs +4.5% PY), and U.S. visits came in ~100 bps better than initial guide. EPS bridge disclosed: +$0.09 SBC, -$0.05 equity-investment loss, +$0.14 FX. The lone misses in the L8Q window were Q2'24 EPS (litigation accrual) and Q3'24 revenue (modest). Magnitude moderation is a function of higher Street bar, not weakening operating performance — operationally Q1'26 is one of the cleanest prints in the cycle.

Guidance Deep Dive

Metric	Prior Guide Mid (Feb'26)	New Guide Range	New Guide Mid	Street Pre-Print	vs Prior	vs Street
FY26 Revenue ($B)	~$4.676B	$4.675B – $4.760B	$4.7175B	~$4.70B	+$42M / +0.9%	+$18M / +0.4%
FY26 Reported Rev Growth	~8.7% mid	8.6% – 10.6%	9.6%	~8.0%	+90 bps	+160 bps
FY26 Organic Rev Growth	~8.0% mid (7-9%)	7.7% – 9.7%	8.7%	~8.0%	+70 bps	+70 bps
FY26 CAG Dx Recurring Organic	9.0% mid	8.7% – 10.7%	9.7%	~9.0%	+70 bps	+70 bps
FY26 EPS	$14.545	$14.45 – $14.90	$14.675	~$14.81	+$0.13 / +0.9%	-$0.135 (FX/equity-loss optics)
FY26 Reported Op Margin	32.25% mid	32.1% – 32.5%	32.3%	—	Maintained	—
FY26 Comparable OM Expansion	30-80 bps	50-90 bps	70 bps	—	+20 bps mid	—
FY26 Net Price Realization	~4%	~4%	~4%	—	Maintained	All raise = volume
FY26 U.S. Clinical Visits	-2% (assumed)	-1.5%	-1.5%	—	+50 bps better	Better than feared
FY26 inVue Dx placements	5,500	5,500 maintained	5,500	—	Maintained (1,100 in Q1)	—
FY26 FX impact (now)	Modest H/W	+~90 bps tailwind	—	—	Flipped to tailwind	—
FY26 FCF conversion	85-95%	85-95%	90%	—	Maintained	—
FY26 Capex	~$180M	~$180M	—	—	Maintained	—
Q2'26 Reported Rev Growth	—	+7.3% – +9.3% (incl. ~60bps FX)	+8.3%	—	—	—
Q2'26 Organic Rev Growth	—	+6.7% – +8.7%	+7.7%	—	—	—
Q2'26 CAG Dx Recurring Organic	—	+8.5% – +10.5% (-50 bps days)	+9.5%	—	—	—
Q2'26 Op Margin	—	33.9% – 34.3%	34.1%	—	—	+10-50 bps comparable

Tone: most positive of the Q2'25 → Q3'25 → Q4'25 → Q1'26 arc — "exceptional start to 2026." Trajectory: Cautiously constructive (Q2'25, "sector headwinds remain") → increasingly confident (Q3'25, "outstanding execution") → confident-but-calibrated (Q4'25, "-2% visit baseline until clear evidence") → decidedly more confident (Q1'26). For the first time this cycle, mgmt explicitly upgraded the underlying industry view — a "modest improvement in our sector outlook for the CAG business" — rather than only IDXX-specific execution. Quality of the raise is high: +70 bps at midpoint to organic CAG Dx recurring, all volume-driven, no price change; built on improved (less bad) U.S. visit assumption (-1.5% vs -2%) and stronger international momentum. EPS midpoint of $14.675 sits ~$0.135 below ~$14.81 Street, but the gap reflects (a) $0.05 Q1 equity-investment loss and (b) Street running at the high end of the prior range; operational pass-through ($0.13) is in line with the rev beat. CEO transition (Mazelsky → Erickson, post-May annual meeting) was managed with continuity messaging — Erickson explicitly endorsed strategy and flagged August Investor Day for any updates. Risk caveats: Middle East fuel/energy volatility, Middle East Water supply-chain disruption (modest, baked in), tariffs at "current laws," wellness visits still pressured (-3%). Watch: 2H comp dynamics — instrument revenue declines as IDXX laps heavy 2025 inVue ramp, requiring F&A unconstrained launch + Cancer Dx menu expansion to carry organic growth into 2H.

Upcoming Catalysts

#	Catalyst	Timing	What to Watch	Read
1	inVue Dx F&A unconstrained launch	Broaden Q2'26; full-volume ramp 2H'26	Step-up in inVue rev/box toward $3,500-$5,500 band; 2H CAG Dx organic re-accel	Most important catalyst — drives 2H story
2	August 2026 Investor Day + CEO transition	August 2026	Erickson AI roadmap (inVue / ezyVet / Vello); LT algo refresh; M&A appetite at 0.5x net leverage	Largest annual sentiment/multiple catalyst
3	Cancer Dx — international launch (EU, AU)	Launched Q1'26	Ref-lab competitive conversions; ~20% of Cancer Dx customers are non-primary IDXX ref-lab accounts	Positive — competitive wedge
4	Cancer Dx menu expansion — mast cell tumor	Later 2026	Ref-lab momentum; menu expansion = mix tailwind	Positive — innovation cadence
5	Cancer Dx — third assay launch	By YE 2026	Sustains ref-lab differentiation into 2027	Positive
6	5,500 inVue Dx placements FY26 (1,100 in Q1)	Through FY26	Quarterly placement cadence; corporate vs independent mix	Slight Q1 miss vs ~1,200-1,300 sell-side; FY reiterated
7	DR50 PLUS DI imaging system ramp	Ongoing FY26	5 consecutive Q record imaging placements; 60% lower dose vs premium peers	Share take from Antech/Mars/Heska imaging
8	U.S. visit stabilization + aging-pet cohort	2H'26 / 2027	5+ yr cohort positive 3rd straight Q on well + non-well; -1% to -2% trend	Multi-year structural tailwind
9	Catalyst menu (PL, cortisol) pull-through	FY26 ongoing	~2% Rapid Assay headwind from PL cannibalization; margin-accretive	Mix-positive
10	Q4'26 price card refresh	Annual cycle	~4% global / ~3.5% U.S. — modeled flat	Pricing stable, volume-driven era
11	Capital deployment / share repo	Ongoing	$361M Q1 buyback; 2.1% diluted share reduction YoY; 0.5x net leverage = M&A optionality	Optionality intact
12	Q2'26 print	Aug 2026 (with Investor Day)	CAG Dx recurring +8.5-10.5% organic; instrument rev declines as 2025 inVue laps	Confirms F&A ramp scaling
13	Competitor watch: Mars/Antech + Zoetis	Ongoing	Mars Cerba Vet/ANTAGENE intl ref-lab build; Zoetis Vetscan Imagyst AI cytology	Direct competitive risk to Cancer Dx / inVue
14	Fuel/macro shock to visits	Ongoing	Middle East energy volatility; lower-end of guide assumes consumer pressure	Tail risk to visit assumption

Street Q&A

#	Analyst (Firm)	Topic	Mgmt Response	Quality
1	Michael Ryskin (BofA)	inVue 1,100 placements vs 5,500 FY target — pacing dynamic?	Jay: tough Q4'25 comp + quarter-to-quarter choppiness from independent vs corporate customer mix. Reaffirmed high confidence in 5,500 FY target; market receptivity very strong.	Well Answered
2	Michael Ryskin (BofA) — follow-up	Improved industry/visit outlook — US or OUS, drivers?	Andrew: Q1 visits at -1% were ~100 bps better than initial guide; aging pets (5+ yrs) positive momentum; NTM avg ~-1.5% matches updated guide. Wellness still pressured; non-well +0.2%. Jay: 5+ yr cohort positive trend in 3rd Q across both well and non-well.	Well Answered — quantified, multi-Q framing
3	Christopher Schott (JPMorgan)	OUS growth: IDEXX execution vs healthier market trends? F&A initial utilization.	Jay: macro pressures on wellness exist intl too, but mix lower; CAG growth reflects multi-year double-digit commercial expansion + ref-lab buildout + localized menu. Mike: F&A controlled launch on track, broadening Q2, unconstrained later this year; AI mast-cell + 1-click pathologist review feedback strong.	Well Answered — attribution + forward path
4	Erin Wright (Morgan Stanley)	Consumables accel — inVue vs IDEXX 360 contracts; when does inVue become "needle-moving"?	Jay: inVue consumables (ear cytology, blood morphology) within expectations and 100% net-new growth. Strong consumables also from double-digit installed-base growth across premium instruments (Catalyst pLipase, cortisol, SediVue).	Partial — confirmed contribution but didn't quantify or give timeline
5	Erin Wright (MS) — follow-up	F&A backlog/preorders + next inVue menu expansion timing?	Jay: ear cytology + blood morphology completed menu; F&A is next; >100-150M cytologies done globally manually as LT TAM. Mike: ~12M F&As/yr but 90%+ of suspicious masses uninvestigated due to manual cost — F&A as standard-of-care expansion.	Partial — TAM yes, backlog/timing no
6	Jonathan Block (Stifel)	1H CAG Dx ~10.25% vs FY mid 9.7% — comps tougher in 2H, what drives 2-yr stack accel?	Andrew: FY raise +70 bps mid driven by global execution, innovation (inVue, Catalyst pLipase/cortisol), expanded utilization, slightly better visits; upper end consistent with current trends. Jay: Ref Lab momentum from Cancer Dx, F&A full-volume in 2H.	Well Answered — specific 2H drivers
7	Jonathan Block (Stifel) — follow-up	Is inVue not yet within $3,500-$5,500 rev/box band? When does it require unconstrained F&A?	Andrew: utilization in line with build, ARE within the band already, including controlled F&A contribution. Mike: "well within the range" before unconstrained F&A; continued upside from F&A TAM.	Well Answered — corrected the premise directly
8	Daniel Clark (Leerink)	Visit guide — fuel-price assumption? Intra-quarter (Jan/Feb/Mar) visit changes?	Andrew: fuel/Middle East dynamics volatile, hard to predict; lower end allows for continued consumer constraint, calibrated to multi-Q trend. Wellness/discretionary remains predominant decline; non-well roughly flat 3 quarters. Don't break out monthly. Jay: intl has grown consistently through prior macro shocks.	Partial — explicitly declined monthly trends
9	Ryan Daniels (William Blair)	Drivers of positive non-well visit inflection — aging pet, pent-up demand — sustainable?	Jay: 5-7 yr cohort (pandemic adoptions) heavily medicalized — doodles/Frenchies — require more care; corporate customers validated; front end of large pandemic adoption cohort aging in; sustainable.	Well Answered — cohort/breed framing
10	Ryan Daniels (Wm Blair) — follow-up	Supply chain disruption — CAG or Water/LPD? Abated? Baked into guide?	Andrew: specific to Water in Middle East; modest pressure factored into outlook; continuing to work through.	Well Answered — direct, specific
11	Daniel Grosslight (Citi)	Force-rank improved CAG Dx outlook — volume vs price vs innovation; biggest swing factor to upper end?	Andrew: pricing unchanged (~4% net global, modestly lower US); the entire 70 bps raise is volume-driven — execution + innovation + dx frequency + improved visits. Jay: volume-driven, double-digit installed-base growth, Cancer Dx, intl commercial expansion.	Well Answered — "100% volume, no pricing change"

Contradictions

#	Topic	Severity	Statement A	Statement B	Why it's a tension
1	InVue Dx placements into corporate accounts	Medium-High — internal-to-same-call	Jay (Q4'25 Q&A to Clark): "We're not placing InVue into corporate practices… but we're now well into the sell-in and placement within the corporate groups."	Andrew (Q4'25 Q&A to Vazquez, same call): "As Jay just highlighted, I think we are placing InVue into corporate accounts at this point."	Jay's first sentence directly contradicts Andrew minutes later (and Jay's own follow-on). Likely a misspeak rather than reversal — but leaves ambiguity on corporate channel penetration. Q1'26 confirms corporate placements are real ("choppiness from independent vs corporate mix"). Implication: corporate is the largest remaining inVue lever; if just beginning, more upside to 5,500; if well underway, slowdown is a concession the bolus is fading.
2	International clinical visit trajectory	Low-Medium	Jay (Q3'25 to Schott): International visits "largely stabilized… stable environment."	Andrew (Q1'26 prepared remarks): International seeing "similar macro pressures affecting visits in most geographies."	"Stable" and "similar macro pressures to U.S. -1 to -2%" cannot both be true. Suggests intl conditions deteriorated or Q3 stabilization was overly optimistic. Bull narrative that 13-16% intl growth algo is unlinked to macro is weakened — intl growth is execution-led against softer macro, not benign macro.
3	Q4'25 instrument trajectory: "solid" vs guide-down	Low	Andrew (Q4'25 prepared remarks): "Solid placement levels for full year 2026 across our premium instrument installed base… 5,500 InVue DX instruments."	Andrew (Q1'26): "Expectations for declines in CAG instrument revenues as we begin lapping significant placements of InVue Dx during 2025."	Not a hard contradiction; framing tension. 5,500 in '26 vs 6,400 in '25 = -14% units AND declining instrument revenue, yet labeled "solid." Investors expecting sustained ~6,000+ inVue cadence should recalibrate — adds modest weight to bear case that inVue tailwind (~200 bps in 2025) becomes net headwind in 2026.

Indirect Read-Throughs

Name	Relationship	What IDXX signaled	Read-through
Zoetis (ZTS)	Animal health peer (not named)	Aging pet 5+ yr cohort (heavily medicalized doodles/Frenchies) inflecting positive on sick visits; ~4% pricing normalized	POSITIVE for sick-care therapeutics; pricing era moderating
Elanco (ELAN)	Animal health peer	Non-well visits +0.2%; chronic-care SKUs benefit from aging cohort	POSITIVE — chronic-care exposure
Antech / Mars Petcare	Direct ref-lab + imaging competitor	Cancer Dx "major differentiator" driving competitive ref-lab transitions; ~20% of Cancer Dx customers are non-primary IDEXX ref-lab accounts; DR50 PLUS DI imaging records	NEGATIVE — IDEXX taking ref-lab + imaging share
Heska legacy (Mars)	Imaging competitor	DR50 PLUS "60% lower dose than premium competitors"; 5 consecutive Q record imaging placements	NEGATIVE — share loss
Zoetis Reference Labs / Vetscan Imagyst	Ref-lab + AI cytology competitor	Cancer Dx oncology IP cited as competitive wedge; F&A AI cytology going unconstrained 2H'26	NEGATIVE — direct AI-cytology competition
Covetrus / Patterson (PDCO)	PIMS / distribution peers	ezyVet cloud-native PIMS "installed base grew double-digits"; "virtually all placements now cloud-based"	NEGATIVE — accelerated obsolescence of on-prem PIMS
Henry Schein (HSIC)	Distribution peer	Corporate customers "capex-active"; aging-pet validation	POSITIVE — equipment financing, corporate channel
Chewy (CHWY) / Trupanion (TRUP)	Pet retail / insurance peers	Wellness visits -3% (discretionary deferred); puppy/wellness funnel pressured	CAUTIOUS — wellness-funnel-dependent businesses pressured
Petco / PetSmart / Tractor Supply (TSCO)	Pet retail	Wellness visit weakness = trade-off behavior	CAUTIOUS — discretionary spend pressure
MWI / Cencora	Animal health distribution	Chronic-care SKU pull-through from aging cohort	POSITIVE — distribution-volume tailwind
Greencross / VetPartners (AU corporate vet)	Corporate vet customer (named indirectly)	"Large corporate group in Australia recently announced inclusion of Cancer DX within their senior wellness plan, no additional charge"	POSITIVE — corporate consolidators bundling premium dx into wellness plans
JAB Holding / NVA / VCA / BluePearl / Mars Vet	US corporate vet customers (generic)	"Corporate customers… validated [aging-pet medicalization]"; quarter-to-quarter inVue placement choppiness from independent vs corporate mix	POSITIVE — corporate buyers active
PetDesk / Weave / Rapport (private SaaS)	Pet-owner engagement SaaS	Vello "continues to gain traction, growing double digits from last quarter"	NEGATIVE — vertically-integrated competitor with bundled pricing
SoundVet / Antech imaging consults	Teleradiology peers	IDEXX Telemedicine "very strong volume growth" via Web PACS integration (50% fewer submission clicks)	NEGATIVE — teleradiology share loss
Multinational large-caps (broad)	FX read-through	USD weakened materially since Feb'26 guide; FY26 FX flipped from headwind to ~90 bps tailwind; Q1 FX = +$14M op income / +$0.14 EPS	POSITIVE — translation tailwind for EU/JP/AU exposure
Middle East logistics-exposed (broad)	Supply-chain	"Middle East region certainly have seen some dynamics going on where supply chain has gotten disrupted" (hit IDEXX Water)	NEGATIVE — verify exposure for industrials, water, ag inputs
BLS Pet Services CPI	Macro KPI	Pet services CPI +5.1% YoY (well above general inflation)	Bullish for IDXX 4% pricing; bearish for owner discretionary
CARE for Pets industry data	Industry KPI	External: -3.1% U.S. visit decline 2025 industry-wide; IDXX same-store -1 to -2% = outperforming on clinic-mix quality	Bullish for IDXX share narrative

Data sourced from Daloopa. Document search is currently in beta; transcript and filing snippets may vary.